[166Dy]镝/[166Ho]钬体内发生器

[166Dy]dysprosium/[166Ho]holmium in vivo generator.

作者信息

Smith S V, Di Bartolo N, Mirzadeh S, Lambrecht R M, Knapp F F, Hetherington E L

机构信息

Biomedicine and Health Program, Australian Nuclear Science and Technology Organisation (ANSTO), New South Wales.

出版信息

Appl Radiat Isot. 1995 Aug;46(8):759-64. doi: 10.1016/0969-8043(94)00149-t.

DOI:10.1016/0969-8043(94)00149-t

PMID:7633391

Abstract

A novel approach for the delivery of 166Ho (t1/2 = 26.6 h) to tissue is via the in vivo decay of its 81.5 h parent, 166Dy-an in vivo generator system. A critical question for the in vivo 166Dy/166Ho generator system is whether translocation of the daughter nucleus occurs. The in vitro and in vivo integrity of the [166Dy]Dy/166Ho-DTPA complex was investigated and results indicated that no translocation of the daughter nucleus occurs subsequent to beta- decay of 166Dy. Biodistribution studies of [166Dy]Dy-DTPA showed that the ratio of 166Dy/166Ho in bone remains constant (+/- 7%) over a 20 h period, indicating no significant in vivo loss of 166Ho from the complex. Increasing the in vivo residence time of [166Dy]Dy-DTPA complex attached to HSA gave similar results.

摘要

一种将166Ho（半衰期t1/2 = 26.6小时）递送至组织的新方法是通过其半衰期为81.5小时的母体166Dy在体内的衰变——一种体内发生器系统。对于体内166Dy/166Ho发生器系统而言，一个关键问题是子核是否会发生移位。对[166Dy]Dy/166Ho - DTPA复合物的体外和体内完整性进行了研究，结果表明，166Dy发生β衰变后，子核不会发生移位。[166Dy]Dy - DTPA的生物分布研究表明，在20小时内，骨中166Dy/166Ho的比例保持恒定（±7%），这表明该复合物中的166Ho在体内没有显著损失。增加附着于HSA的[166Dy]Dy - DTPA复合物在体内的停留时间也得到了类似结果。